Summing up 100 years of asthma

Respiratory Medicine

Volumn 101, Issue 3, 2007, Pages 378-388

  Diamant, Zuzana ^a   Diderik Boot, J ^a   Christian Virchow, J ^b  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Asthma; Historical review; Pathology; Therapy

Indexed keywords

ADRENALIN; AMINOPHYLLINE; ATROPINE; BELLADONNA ALKALOID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBUTEROL; CHLORPROMAZINE; CILOMILAST; CLENBUTEROL; COCAINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; FORMOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; LONG ACTING DRUG; MENTHOL; MORPHINE; OPIATE DERIVATIVE; PLANT EXTRACT; ROFLUMILAST; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ARTICLE; ASTHMA; BRONCHOSPASM; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG COST; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERTENSION; HYPNOSIS; LIFESTYLE; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; HISTAMINE H1 ANTAGONISTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; KETOTIFEN; LEUKOTRIENE ANTAGONISTS; PHENOTYPE; XANTHINES;

EID: 33846702601     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.12.004     Document Type: Article

References (149)

1. Cserhati E. The history of bronchial asthma from the ancient times till the middle ages. Acta Physiol Hung 91 3 and 4 (2004) 243-261
2. Ellul-Micallef R. Asthma: a look at the past. Br J Dis Chest 70 (1976) 112-116
3. Cserhati E. The history of bronchial asthma from the Renaissance till the beginning of the twentieth century. Acta Physiol Hung 92 2 (2005) 181-192
4. Salter H.H. On asthma: its pathology and treatment (1860), John Churchill, London
5. Osler W. Bronchial asthma. Principles and practice of medicine (1892), D. Appleton & Co., New York
6. Schwartz R.S. Paul Ehrlich's magic bullets. N Engl J Med 350 11 (2004) 1079-1080
7. Holgate S.T. Lessons learnt from the epidemic of asthma. QJM 97 5 (2004) 247-257
8. Halls Dally J.F. Asthma and its treatment. Br J Tuber 22 3 (1928) 146-147
9. Crocket J.A. A psychosomatic aspect of asthma. Br J Dis Chest 53 2 (1959) 128-141
10. Lommatzsch M., Schloetcke K., Klotz J., Schuhbaeck K., Zingler D., Zingler C., et al. Brain-derived neurotrophic factor in platelets and airflow limitation in asthma. Am J Respir Crit Care Med 171 2 (2005) 115-120
11. Virchow J.C., Julius P., Lommatzsch M., Luttmann W., Renz H., and Braun A. Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation. Am J Respir Crit Care Med 158 6 (1998) 2002-2005
12. Hofbauer L. Asthma and tuberculosis. Br J Tuber 25 2 (1931) 77-79
13. Rackemann F.M., Burrage W.S., and Irwin J.W. Intrinsic asthma. Postgrad Med 8 2 (1950) 134-140
14. Turner Warwick M. Provoking factors in asthma. Br J Dis Chest 65 (1971) 1-20
15. Curry J.J. The action of histamine on the respiratory tract in normal and asthmatic subjects. J Clin Invest 25 6 (1946) 785-791
16. Ellul-Micallef R. Airway smooth muscle in health and in asthma. Br J Dis Chest 67 2 (1973) 107-113
17. Laitinen L.A., Heino M., Laitinen A., Kava T., and Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 131 4 (1985) 599-606
18. Jeffery P.K., Laitinen A., and Venge P. Biopsy markers of airway inflammation and remodelling. Respir Med 94 Suppl F (2000) S9-S15
19. Niimi A., Matsumoto H., Takemura M., Ueda T., Chin K., and Mishima M. Relationship of airway wall thickness to airway sensitivity and airway reactivity in asthma. Am J Respir Crit Care Med 168 8 (2003) 983-988
20. Lombardi C., Passalacqua G., Gargioni S., Senna G., Ciprandi G., Scordamaglia A., et al. The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years. Respir Med 95 1 (2001) 9-12
21. Crocket J.A. Chlorpromazine in asthma, chronic bronchitis and emphysema. Br J Tuber Dis Chest 50 3 (1956) 221-224
22. Chapman B.J., McDonald C., Capewell S., Frame M.H., and Crompton G.K. Enprofylline in chronic asthma. Br J Dis Chest 82 4 (1988) 354-359
23. Widdicombe J.G., and Sterling G.M. The autonomic nervous system and breathing. Arch Intern Med 126 2 (1970) 311-329
24. Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., and Pavord I.D. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346 22 (2002) 1699-1705
25. Burns G.P., and Gibson G.J. The apparent response of airway function to deep inspiration depends on the method of assessment. Respir Med 95 4 (2001) 251-257
26. Halayko A.J., and Amrani Y. Mechanisms of inflammation-mediated airway smooth muscle plasticity and airways remodeling in asthma. Respir Physiol Neurobiol 137 2 and 3 (2003) 209-222
27. Wuthrich B. [Atopy: definition-pathogenesis]. Padiatr Padol 25 4 (1990) 215-226
28. White J., and Eiser N.M. The role of histamine and its receptors in the pathogenesis of asthma. Br J Dis Chest 77 (1983) 215-226
29. MacFarlane P.I., and Heaf D.P. Selective histamine blockade in childhood asthma; the effect of terfenadine on resting bronchial tone and exercise induced bronchoconstriction. Respir Med 83 1 (1987) 19-24
30. Bousquet J., Godard P., and Michel F.B. Antihistamines in the treatment of asthma. Eur Respir J 5 9 (1992) 1137-1142
31. Mueller R., Chanez P., Campbell A.M., Bousquet J., Heusser C., and Bullock G.R. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 90 2 (1996) 79-85
32. Sullivan R. Inflammatory basis of asthma. Respir Med 87 4 (1993) 319
33. BJERMER L., and Diamant Z. Current and emerging nonsteroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy. Treat Respir Med 3 4 (2004) 235-246
34. Leckie MJ, Brinke AT, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-respons[x00ec]veness, and the late asthmatic response. Lancet 356(9248); 2144-8.
35. Green R.H., Brightling C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 9347 (2002) 1715-1721
36. Puxeddu I., Ribatti D., Crivellato E., and Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 116 3 (2005) 531-536
37. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 33 12 (2003) 1622-1628
38. Shapiro S.D., and Owen C.A. ADAM-33 surfaces as an asthma gene. N Engl J Med 347 12 (2002) 936-938
39. Tony J.C. Granulocyte-macrophage colony stimulating factor and bronchial asthma-a hypothesis for novel therapeutic options. Respir Med 89 10 (1995) 713
40. Ross I. Bronchial asthma in Malaysia. Br J Dis Chest 78 4 (1984) 369-375
41. Skin tests and clinical features of asthma. A report to the research committee of the British Thoracic and Tuberculosis Association. Br J Dis Chest 69 2 (1975) 125-136
42. Rose G.A. Clinical features of polyarteritis nodosa with lung involvement. Br J Tuber Dis Chest 51 2 (1957) 113-122
43. Comparison of atopic and non-atopic patients dying of asthma. Br J Dis Chest 81 (1987) 30-34
44. Ulrik C.S., Backer V., Dirksen A., Pedersen M., and Koch C. Extrinsic and intrinsic asthma from childhood to adult age: a 10-yr follow-up. Respir Med 89 8 (1995) 547-554
45. OGILVIE A.G. The treatment of patients with severe asthma and chronic bronchitis. Br J Tuber Dis Chest 52 2 (1958) 126-133
46. Meadway J. Asthma and Atopy in workers with an epoxy adhesive. Br J Dis Chest 74 2 (1980) 149-154
47. Anderson S.D., Silverman M., Konig P., and Godfrey S. Exercise-induced asthma. Br J Dis Chest 69 1 (1975) 1-39
48. Pelaia G., Vatrella A., Gallelli L., Renda T., Cazzola M., Maselli R., et al. Respiratory infections and asthma. Respir Med 100 5 (2006) 775-784
49. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Bethersda/Martyland: NHLBI/WHO workshop report. Last updated: 2005. 1-1-1995.
50. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 368(9537):780-93.
51. Peters S.P., Ferguson G., Deniz Y., and Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 100 7 (2006) 1139-1151
52. OGILVIE A.G. The treatment of patients with severe asthma and chronic bronchitis. Br J Tuber Dis Chest 52 2 (1958) 126-133
53. Wardman A.G., Binns V., Clayden A.D., and Cooke N.J. The diagnosis and treatment of adults with obstructive airways disease in general practice. Br J Dis Chest 80 1 (1986) 19-26
54. Belcher J.R. The surgical treatment of asthma. Br J Dis Chest 55 2 (1961) 77-85
55. Brown O.H. Treatment of asthma. Asthma: presenting an exposition of the nonpassive expiration theory (1917), C.V. Mosby, St Louis pp. 265-88
56. Hirsch S. Klinischer und experimenteller beitrag zur kramp-flösenden wirkung der purin derivate. Klin Wochenschr 1 (1922) 615-618
57. Terr A.I., and Bloch D.A. Trends in asthma therapy in the United States: 1965-1992. Ann Allergy Asthma Immunol 76 3 (1996) 273-281
58. Barnes P.J. Current therapies for asthma. Promise and limitations. Chest 111 2 (1997) 17S-26S
59. Eason J., and Markowe H.L. Aminophylline toxicity-how many hospital asthma deaths does it cause?. Respir Med 83 3 (1989) 219-226
60. British guideline on the management of asthma. Thorax 2003; 58(Suppl 1): i1-94.
61. Davies B., Brooks G., and Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med 92 2 (1998) 256-263
62. Reed C.E., Offord K.P., Nelson H.S., Li J.T., and Tinkelman D.G. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. J Allergy Clin Immunol 101 1, Part 1 (1998) 14-23
63. Price J., and Kemp J. The problems of treating adolescent asthma: what are the alternatives to inhaled therapy?. Respir Med 93 10 (1999) 677-684
64. Barnes P.J. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 167 6 (2003) 813-818
65. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. PNAS 99 13 (2002) 8921-8926
66. Evans D.J., Taylor D.A., Zetterstrom O., Chung K.F., O'Connor B.J., and Barnes P.J. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337 20 (1997) 1412-1419
67. Ukena D., Harnest U., Sakalauskas R., Magyar P., Vetter N., Steffen H., et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 10 12 (1997) 2754-2760
68. Yasui K., Hu B., Nakazawa T., Agematsu K., and Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 100 7 (1997) 1677-1684
69. Boswell-Smith V., Cazzola M., and Page C.P. Are phosphodiesterase 4 inhibitors just more theophylline?. J Allergy Clin Immunol 117 6 (2006) 1237-1243
70. Myou S., Fujimura M., Kamio Y., Hirose T., Kita T., Tachibana H., et al. Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br J Clin Pharmacol 55 4 (2003) 341-346
71. Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533 1-3 (2006) 110-117
72. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365(9454): 167-75.
73. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157 2 (1998) 351-370
74. Solis-Cohen S. The use of adrenal substances in the treatment of asthma. J Am Med Assoc 34 (1900) 1164-1166
75. Sears M.R., and Lotvall J. Past, present and future-[beta]2-adrenoceptor agonists in asthma management. Respir Med 99 2 (2005) 152-170
76. Waldeck B. [beta]-Adrenoceptor agonists and asthma-100 years of development. Eur J Pharmacol 445 1 and 2 (2002) 1-12
77. Lands A.M., Luduena F.P., and Buzzo H.J. Differentiation of receptors responsive to isoproterenol. Life Sci 6 21 (1967) 2241-2249
78. Ahlquist R.P. A study Of The adrenotropic receptors. Am J Physiol 153 3 (1948) 586-600
79. Bergman J., Persson H., and Wetterlin K. 2 new groups of selective stimulants of adrenergic beta-receptors. Experientia 25 9 (1969) 899-901
80. Brittain R.T., Farmer J.B., Jack D., Martin L.E., and Simpson W.T. Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha 1,alpha 3-diol (AH.3365): a selective beta-adrenergic stimulant. Nature 219 156 (1968) 862-863
81. Engelhardt G. Profile of pharmacological actions of NAB 365 (clenbuterol), a novel broncholytic agent with selective activity on adrenergic beta2-receptors (author's transl). Arzneimittelforschung 26 7a (1976) 1404-1420
82. O'Donnell S.R. A selective [beta]-adrenoreceptor stimulant (Th1165a) related to orciprenaline. Eur J Pharmacol 12 1 (1970) 35-43
83. Johnson M. Salmeterol. Med Res Rev 15 3 (1995) 225-257
84. Bartow R.A., and Brogden R.N. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 55 2 (1998) 303-322
85. Cazzola M., Matera M.G., and Lotvall J. Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Invest Drugs 14 7 (2005) 775-783
86. Li X., Ward C., Thien F., Bish R., Bamford T., Bao X., et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160 5, Part 1 (1999) 1493-1499
87. Reid D.W., Ward C., Wang N., Zheng L., Bish R., Orsida B., et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 21 6 (2003) 994-999
88. Mc Ivor R., Pizzichini E., Turner M.O., Hussack P., Hargreave F.E., et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158 3 (1998) 924-930
89. Sears M.R., Taylor D.R., Print C.G., Lake D.C., Li Q.Q., Flannery E.M., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336 8728 (1990) 1391-1396
90. Cheung D., Timmers M.C., Zwinderman A.H., Bel E.H., Dijkman J.H., and Sterk P.J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327 17 (1992) 1198-1203
91. Haney S., and Hancox R.J. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 99 5 (2005) 566-571
92. van der Woude H.J., Winter T.H., and Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting {beta}2 agonists. Thorax 56 7 (2001) 529-535
93. van Veen A., Weller F.R., Wierenga E.A., Jansen H.M., and Jonkers R.E. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther 16 3 (2003) 153-161
94. Israel E., Chinchilli V.M., Ford J.G., Boushey H.A., Cherniack R., Craig T.J., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 9444 (2004) 1505-1512
95. Wechsler M.E., Lehman E., Lazarus S.C., Lemanske Jr. R.F., Boushey H.A., Deykin A., et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173 5 (2006) 519-526
96. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M., and the SMART Study Group. The salmeterol multicenter asthma research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 1 (2006) 15-26
97. Hasford J., and Virchow J.C. Excess mortality in patients with asthma on long-acting {beta}2-agonists. Eur Respir J 28 5 (2006) 900-902
98. Gross N.J. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 533 1-3 (2006) 36-39
99. Teale C., Morrison J.F., Muers M.F., and Pearson S.B. Response to nebulized ipratropium bromide and terbutaline in acute severe asthma. Respir Med 86 3 (1992) 215-218
100. Orr T.S. Mast cells and allergic asthma. Br J Dis Chest 67 2 (1973) 87-106
101. Kuzemko J.A. Twenty years of sodium cromoglycate treatment: a short review. Respir Med 83 Suppl A (1989) 11-14
102. Church M.K., and Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 90 2 (1987) 421-429
103. Pearce F.L. Effect of nedocromil sodium on mediator release from mast cells. J Allergy Clin Immunol 92 1, Part 2 (1993) 155-158
104. Sridhar A.V., and McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 3 (2006) CD004108
105. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 343 15 (2000) 1054-1063
106. Carra S., Gagliardi L., Zanconato S., Scollo M., Azzolin N., Zacchello F., et al. Budesonide but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic children. Respir Med 95 9 (2001) 734-739
107. Kannisto S., Voutilainen R., Remes K., and Korppi M. Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. Pediatr Allergy Immunol 13 1 (2002) 24-30
108. Hoshino M., Nakamura Y., Sim J.J., and Tomioka H. A comparative study of the effects of ketotifen, disodium cromoglycate, and beclomethasone dipropionate on bronchial mucosa and asthma symptoms in patients with atopic asthma. Respir Med 92 7 (1998) 942-950
109. Holgate S.T. The efficacy and therapeutic position of nedocromil sodium. Respir Med 90 7 (1996) 391-394
110. Spooner C.H., Saunders L.D., and Rowe B.H. Nedocromil sodium for preventing exercise-induced bronchoconstriction. Cochrane Database Syst Rev 1 (2002) CD001183
111. Canny G.J., Reisman J., and Levison H. Does ketotifen have a steroid-sparing effect in childhood asthma?. Eur Respir J 10 1 (1997) 65-70
112. Eiser N. The effect of a beta 2-adrenergic agonist and a histamine H1-receptor antagonist on the late asthmatic response to inhaled antigen. Respir Med 85 5 (1991) 393-399
113. Monie R.D., Smith A.P., Leopold D., Anderson G., Davies B.H., and Thomas G.O. A double-blind clinical trial of ketotifen and disodium cromoglycate in bronchial asthma. Br J Dis Chest 76 4 (1982) 383-389
114. Stratton D., Carswell F., Hughes A.O., Fysh W.J., and Robinson P. Double-blind comparisons of slow-release theophylline, ketotifen and placebo for prophylaxis of asthma in young children. Br J Dis Chest 78 2 (1984) 163-167
115. Bordley J.E., and Carey R.A. Preliminary observations on the effect of adrenocorticotropic hormone in allergic diseases. Bull Johns Hopkins Hosp 85 5 (1949) 396-398
116. Schwartz E. Oral cortisone therapy in intractable bronchial asthma. J Am Med Assoc 147 18 (1951) 1734-1737
117. Brown H.M., Storey G., and George W.H. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1 5800 (1972) 585-590
118. Clark T.J. Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet 1 7765 (1972) 1361-1364
119. Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1975; 2(7933): 469-73.
120. A controlled trial of inhaled corticosteroids in patients receiving prednisone tablets for asthma. Br J Dis Chest 70 (1976) 95-103
121. Stafford R.S., Ma J., Finkelstein S.N., Haver K., and Cockburn I. National trends in asthma visits and asthma pharmacotherapy, 1978-2002. J Allergy Clin Immunol 111 4 (2003) 729-735
122. McFadden Jr. E.R. A century of asthma. Am J Respir Crit Care Med 170 3 (2004) 215-221
123. Yeadon M., and Diamant Z. New and exploratory therapeutic agents for asthma. 1st ed (2000), Marcel Dekker, New York
124. Sont J.K., Willems L.N., Bel E.H., Van Krieken J.H., Vandenbroucke J.P., and Sterk P.J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159 4, Part 1 (1999) 1043-1051
125. Barnes P.J. The role of inflammation and anti-inflammatory medication in asthma. Respir Med 96 Suppl 1 (2002) S9-S15
126. Barnes P.J. Corticosteroids: the drugs to beat. Eur J Pharmacol 533 1-3 (2006) 2-14
127. Nave R., Zech K., and Bethke T.D. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 61 3 (2005) 203-208
128. Richter K., Kanniess F., Biberger C., Nave R., and Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 45 2 (2005) 146-152
129. Zietkowski Z., Bodzenta-Lukaszyk A., Tomasiak M.M., Szymanski W., and Skiepko R. Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. Respir Med 100 9 (2006) 1651-1656
130. Dworski R., and Sheller J. Inhaled steroids in asthma. Compr Ther 18 3 (1992) 3-5
131. Ward C., and Walters H. Airway wall remodelling: the influence of corticosteroids. Curr Opin Allergy Clin Immunol 5 1 (2005) 43-48
132. Feldberg W., Holden H.F., and Kellaway C.H. The formation of lysocithin and of a muscle-stimulating substance by snake venoms. J Physiol 94 2 (1938) 232-248
133. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 4597 (1983) 568-575
134. Diamant Z., and Sampson A.P. Anti-inflammatory mechanisms of leukotriene modulators. Clin Exp Allergy 29 11 (1999) 1449-1453
135. Bjermer L., and Diamant Z. Current and emerging nonsteroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy. Treat Respir Med 3 4 (2004) 235-246
136. Lane S.J. Leukotriene antagonism in asthma and rhinitis. Respir Med 92 6 (1998) 795-809
137. Ind P.W. Anti-leukotriene intervention: is there adequate information for clinical use in asthma?. Respir Med 90 10 (1996) 575-586
138. Bisgaard H., Zielen S., Garcia-Garcia M.L., Johnston S.L., Gilles L., Menten J., et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 171 4 (2005) 315-322
139. Bjermer L., Bisgaard H., Bousquet J., Fabbri L.M., Greening A., Haahtela T., et al. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT investigation of montelukast as a partner agent for complementary therapy-trial). Respir Med 94 6 (2000) 612-621
140. Diamant Z., and van der M.T. Treating asthma: is there a place for leukotriene receptor antagonists?. Respir Med 99 6 (2005) 655-662
141. Virchow J.C., and Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 100 11 (2006) 1952-1959
142. Szczeklik A., and Nizankowska E. Asthma improved by aspirin-like drugs. Br J Dis Chest 77 (1983) 153-158
143. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 100 11 (2006) 1907-1917
144. Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 3 (2005) 309-316
145. Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59 7 (2004) 709-717
146. Berry M.A., Hargadon B., Shelley M., Parker D., Shaw D.E., Green R.H., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354 7 (2006) 697-708
147. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., et al. Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 12 (2005) 1012-1018
148. Rouhani F.N., Meitin C.A., Kaler M., Miskinis-Hilligoss D., Stylianou M., and Levine S.J. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 99 9 (2005) 1175-1182
149. Diamant Z., Kuperus J., Baan R., Nietzmann K., Millet S., Mendes P., et al. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin Exp Allergy 35 8 (2005) 1080-1087